Peripheral, but Not Central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats

Diabetes

Volumn 57, Issue 11, 2008, Pages 2977-2991

  Nogueiras, Ruben ^a,b,c   Veyrat Durebex, Christelle ^d   Suchanek, Paula M ^e   Klein, Marcella ^d   Tschöp, Johannes ^a   Caldwell, Charles ^a   Woods, Stephen C ^a   Wittmann, Gabor ^f   Watanabe, Masahiko ^g   Liposits, Zsolt ^f   Fekete, Csaba ^f,h   Reizes, Ofer ⁱ   Rohner Jeanrenaud, Francoise ^d   Tschöp, Matthias H ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c Instituto de Salud Carlos III   (Spain)

^d UNIVERSITY OF GENEVA   (Switzerland)

^e PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^f INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^g HOKKAIDO UNIVERSITY   (Japan)

^h TUFTS MEDICAL CENTER   (United States)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; GLUCOSE; INSULIN; LIPID; RIMONABANT; ACETYL COENZYME A CARBOXYLASE; FATTY ACID SYNTHASE; LIPOPROTEIN LIPASE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; ENERGY METABOLISM; FOOD INTAKE; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; INSULIN SENSITIVITY; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; ADIPOSE TISSUE; ANIMAL; DRUG ANTAGONISM; EATING; FAT INTAKE; GENETICS; GLUCOSE CLAMP TECHNIQUE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WISTAR RAT;

ACETYL-COA CARBOXYLASE; ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; CHROMATOGRAPHY, LIQUID; DIETARY FATS; EATING; FATTY ACID SYNTHETASE COMPLEX; GLUCOSE CLAMP TECHNIQUE; LIPID METABOLISM; LIPOPROTEIN LIPASE; MALE; MASS SPECTROMETRY; OBESITY; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIGLYCERIDES;

EID: 58149128824     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db08-0161     Document Type: Article

References (52)

1. Williams CM, Kirkham TC: Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 143: 315-317, 1999
2. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G: Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822-825, 2001
3. Breivogel CS, Sim LJ, Childers SR: Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J Pharmacol Exp Ther 282:1632-1642, 1997
4. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM: Immunohisto- chemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83:393-411, 1998
5. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389-1397, 2005
6. Despres JP, Golay A, Sjostrom L: Effects of Rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121-2134, 2005
7. Pagotto U, Pasquali R: Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet 365:1363-1364, 2005
8. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometa- bolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295:761-775, 2006
9. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368:1660-1672, 2006
10. Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, Lu K, Yuan J, Sanabria-Bohorquez SM, Stoch A, Stevens C, Fong TM, De Lepeleire I, Cilissen C, Cote J, Rosko K, Gendrano IN 3rd, Nguyen AM, Gumbiner B, Rothenberg P, de Hoon J, Bormans G, Depre M, Eng WS, Ravussin E, Klein S, Blundell J, Herman GA, Burns HD, Hargreaves RJ, Wagner J, Gottesdie- ner K, Amatruda JM, Heymsfield SB: The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 7:68-78, 2008
11. Kirkham TC: Taranabant cuts the fat: new hope for cannabinoid-based obesity therapies? Cell Metab 7:1-2, 2008
12. Jo YH, Chen YJ, Chua SC Jr, Talmage DA, Role LW: Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit. Neuron 48:1055-1066, 2005
13. Malcher-Lopes R, Di S, Marcheselli VS, Weng FJ, Stuart CT, Bazan NG, Tasker JG: Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J Neurosci 26:6643-6650, 2006
14. Hentges ST, Low MJ, Williams JT: Differential regulation of synaptic inputs by constitutively released endocannabinoids and exogenous cannabinoids. J Neurosci 25:9746-9751, 2005
15. Matias I, Vergoni AV, Petrosino S, Ottani A, Pocai A, Bertolini A, Di Marzo V: Regulation of hypothalamic endocannabinoid levels by neuropeptides and hormones involved in food intake and metabolism: insulin and melanocortins. Neuropharmacology 54:206-212, 2008
16. Kunos G: Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system? Am J Med 120:S18-S24, 2007
17. Serrano A, Del Arco I, Javier Pavon F, Macias M, Perez-Valero V, Rodriguez de Fonseca F: The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology 54:226-234, 2008
18. Tallett AJ, Blundell JE, Rodgers RJ: Behaviourally-selective hypophagic effects of naloxone in non-deprived male rats presented with palatable food. Behav Brain Res 187:417-427, 2008
19. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie P: Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284:R345-R353, 2003
20. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrie P: The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63:908-914, 2003
21. Kunz I, Meier MK, Bourson A, Fisseha M, Schilling W: Effects of rimon- abant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats. Int J Obes (Lond) 32:863-870, 2008
22. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112:423-431, 2003
23. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P: CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28:640-648, 2004
24. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, Kunos G: Endocannabi- noid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115:1298-1305, 2005
25. Jeong WI, Osei-Hyiaman D, Park O, Liu J, Batkai S, Mukhopadhyay P, Horiguchi N, Harvey-White J, Marsicano G, Lutz B, Gao B, Kunos G: Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 7:227-235, 2008
26. Liu YL, Connoley IP, Wilson CA, Stock MJ: Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 29:183-187, 2005
27. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, Petrosino S, Hoareau L, Festy F, Pasquali R, Roche R, Maj M, Pagotto U, Monteleone P, Di Marzo V: Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91:3171-3180, 2006
28. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S, Pacher P, Schon MR, Jordan J, Stumvoll M: Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55:3053-3060, 2006
29. Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, Despres JP, Di Marzo V: Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 31:692-699, 2007
30. Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, Milan G, Bianchi K, Rizzuto R, Bernante P, Federspil G, Vettor R: The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylino- sitol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 92:4810-4819, 2007
31. D'Eon TM, Pierce KA, Roix JJ, Tyler A, Chen H, Teixeira SR: The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids. Diabetes 57:1262-1268, 2008
32. Pagotto U, Cervino C, Vicennati V, Marsicano G, Lutz B, Pasquali R: How many sites of action for endocannabinoids to control energy metabolism? Int J Obes (Lond) 30 (Suppl. 1):S39-S43, 2006
33. Horvath TL: The unfolding cannabinoid story on energy homeostasis: central or peripheral site of action? Int J Obes (Lond) 30 (Suppl. 1):S30-S32, 2006
34. Nogueiras R, Rohner-Jeanrenaud F, Woods SC, Tschop MH: The endocan- nabinoid system and the control of glucose homeostasis. J Neuroendocri-nol 20 (Suppl. 1):147-151, 2008
35. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R: The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27:73-100, 2006
36. Rohner-Jeanrenaud F, Walker CD, Greco-Perotto R, Jeanrenaud B: Central corticotropin-releasing factor administration prevents the excessive body weight gain of genetically obese (fa/fa) rats. Endocrinology 124:733-739, 1989
37. Verty AN, McFarlane JR, McGregor IS, Mallet PE: Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology 145:3224-3231, 2004
38. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, Penarier G, Soubrie P, Le Fur G, Galiegue S, Casellas P: The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 19:1567-1569, 2005
39. Vettor R, Zarjevski N, Cusin I, Rohner-Jeanrenaud F, Jeanrenaud B: Induction and reversibility of an obesity syndrome by intracerebroventric- ular neuropeptide Y administration to normal rats. Diabetologia 37:1202-1208, 1994
40. Terrettaz J, Assimacopoulos-Jeannet F, Jeanrenaud B: Severe hepatic and peripheral insulin resistance as evidenced by euglycemic clamps in genetically obese fa/fa rats. Endocrinology 118:674-678, 1986
41. Herbert V, Lau KS, Gottlieb CW, Bleicher SJ: Coated charcoal immunoas-say of insulin. J Clin Endocrinol Metab 25:1375-1384, 1965
42. Lopez M, Lelliott CJ, Tovar S, Kimber W, Gallego R, Virtue S, Blount M, Vazquez MJ, Finer N, Powles TJ, O'Rahilly S, Saha AK, Dieguez C, Vidal-Puig AJ: Tamoxifen-induced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-CoA. Diabetes 55:1327-1336, 2006
43. Nogueiras R, Wiedmer P, Perez-Tilve D, Veyrat-Durebex C, Keogh JM, Sutton GM, Pfluger PT, Castaneda TR, Neschen S, Hofmann SM, Howles PN, Morgan DA, Benoit SC, Szanto I, Schrott B, Schurmann A, Joost HG, Hammond C, Hui DY, Woods SC, Rahmouni K, Butler AA, Farooqi IS, O'Rahilly S, Rohner-Jeanrenaud F, Tschop MH: The central melanocortin system directly controls peripheral lipid metabolism. J Clin Invest 117: 3475-3488, 2007
44. Matias I, Di Marzo V: Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 18:27-37, 2007
45. Di Marzo V, Matias I: Endocannabinoid control of food intake and energy balance. Nat Neurosci 8:585-589, 2005
46. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA: Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 167:103-111, 2003
47. Xie S, Furjanic MA, Ferrara JJ, McAndrew NR, Ardino EL, Ngondara A, Bernstein Y, Thomas KJ, Kim E, Walker JM, Nagar S, Ward SJ, Raffa RB: The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism-or inverse agonism-as potential obesity treatment and other therapeutic use. J Clin Pharm Ther 32:209-231, 2007
48. Rodriguez de Fonseca F, Carrera MR, Navarro M, Koob GF, Weiss F: Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276:2050-2054, 1997
49. Alonso R, Voutsinos B, Fournier M, Labie C, Steinberg R, Souilhac J, Le Fur G, Soubrie P: Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function. Neuroscience 91:607-620, 1999
50. Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M: The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 69:471-478, 2006
51. Bermudez-Siva FJ, Serrano A, Diaz-Molina FJ, Sanchez Vera I, Juan-Pico P, Nadal A, Fuentes E, Rodriguez de Fonseca F: Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol 531:282-284, 2006
52. Gasperi V, Fezza F, Pasquariello N, Bari M, Oddi S, Agro AF, Maccarrone M: Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci 64:219-229, 2007